Antibiotic maker Targanta aims for $86.3M IPO
Targanta Therapeutics, a Cambridge, Mass. drug developer at work on a new generation of antibiotics, hopes to raise $86.3 million in an initial offering, according to an SEC filing. The company didn’t specify how many shares it plans to offer or what price it hopes they fetch.
Formerly known as PhageTech, Targanta moved its headquarters to Cambridge from Montreal last year. At about the same time, it brought on a new CEO, Mark Leuchtenberger, whose previous… Continue Reading
How drug reps do that thing they do
Two fascinating papers in the open-access journal PLoS Medicine turn a spotlight on the practice of “detailing” — the office visits that drug-industry salespeople use to flatter and manipulate their way into the good graces of the doctors they want to influence.
The first and most eye-opening paper is co-authored by Shahram Ahari, a former Eli Lilly sales rep, and Adriane Fugh-Berman, a Georgetown University professor who researches drug marketing. Together, the two outline a variety of… Continue Reading